RecruitingMultiple Myeloma
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.
Sponsor: Christopher Strouse
You may qualify if…
- ✓ To be eligible to participate in this study, an individual must meet all of the following criteria:
- ✓ Willingness and ability to provide signed and dated informed consent form.
- ✓ Stated willingness to comply with all study procedures and availability for the duration of the study.
- ✓ Aged 18 years of older.
- ✓ Diagnosis with multiple myeloma, per IMWG Consensus Criteria.20
- ✓ Planned for treatment with teclistamab, or talquetamab per standard of care, label indications.15
- ✓ Prior exposure to any of the following types of T-cell engaging therapies.
- ✓ 1. Anti-BCMA x CD3 bispecific antibody (for example: teclistamab, elranatamab)
You may not qualify if…
- ✕ An individual who meets any of the following criteria will be excluded from participation in this study:
- ✕ Participants whose multiple myeloma is progressing at a rapid pace requiring immediate anti-myeloma therapy per assessment by the principal investigator or enrolling investigator are excluded.
- ✕ Excluded concomitant medication exposures:
- ✕ Exposure to corticosteroids within 1 week of treatment start
- ✕ Exposure to calcineurin inhibitor or mTOR inhibitors (tacrolimus, everolimus, temsirolimus, sirolimus)
- ✕ Immunomodulatory monoclonal antibodies targeting tumor necrosis factor alpha (e.g. infliximab), interleukin 6 (e.g. siltuximab),
- ✕ Janus kinase inhibitors (e.g. ruxolitinib)
- ✕ Any other investigational drug within 28 days
Where it's recruiting
Iowa
Iowa City
Source: ClinicalTrials.gov · NCT07581704 · last updated 2026-06-04